By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Tissue-based cancer diagnostics shop BioMarker Strategies has raised $1.1 million of a targeted $4 million round, a company executive confirmed.

In an e-mail to GenomeWeb Daily News, BioMarker Strategies President Scott Allocco said that funds from the round will be used to support the first clinical use of its flagship platform, called SnapPath, in patients with advanced melanoma.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.